Eli Lilly and Company (NYSE:LLY) EVP Sells $7,638,150.00 in Stock

Eli Lilly and Company (NYSE:LLY) EVP Patrik Jonsson sold 6,500 shares of the stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $1,175.10, for a total transaction of $7,638,150.00. Following the transaction, the executive vice president owned 54,147 shares of the company’s stock, valued at $63,628,139.70. This represents a 10.72% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Eli Lilly and Company Stock Performance

Eli Lilly and Company stock traded up $43.95 during mid-day trading on Tuesday, reaching $1,227.11. The company’s stock had a trading volume of 2,449,913 shares, compared to its average volume of 3,103,126. The firm’s fifty day moving average price is $1,171.52 and its two-hundred day moving average price is $1,053.72. The company has a debt-to-equity ratio of 1.41, a quick ratio of 1.00 and a current ratio of 1.35. Eli Lilly and Company has a 12-month low of $685.15 and a 12-month high of $1,249.45. The company has a market capitalization of $1.16 trillion, a P/E ratio of 41.18, a PEG ratio of 1.39 and a beta of 0.51.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Wednesday, August 5th. The company reported $8.38 earnings per share (EPS) for the quarter, topping the consensus estimate of $6.40 by $1.98. The firm had revenue of $22.97 billion for the quarter, compared to the consensus estimate of $20.82 billion. Eli Lilly and Company had a return on equity of 97.83% and a net margin of 33.53%.The business’s quarterly revenue was up 47.7% on a year-over-year basis. During the same quarter in the prior year, the business posted $6.31 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 35.500-36.500 EPS. Sell-side analysts predict that Eli Lilly and Company will post 36.35 EPS for the current fiscal year.

Eli Lilly and Company Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, September 10th. Shareholders of record on Friday, August 14th will be issued a dividend of $1.73 per share. This represents a $6.92 dividend on an annualized basis and a yield of 0.6%. The ex-dividend date of this dividend is Friday, August 14th. Eli Lilly and Company’s payout ratio is presently 23.22%.

Hedge Funds Weigh In On Eli Lilly and Company

A number of hedge funds and other institutional investors have recently modified their holdings of the company. Osbon Capital Management LLC purchased a new position in shares of Eli Lilly and Company during the fourth quarter worth approximately $25,000. Basso Capital Management L.P. purchased a new stake in shares of Eli Lilly and Company in the 4th quarter valued at $30,000. E Fund Management Hong Kong Co. Ltd. boosted its stake in shares of Eli Lilly and Company by 342.9% in the 4th quarter. E Fund Management Hong Kong Co. Ltd. now owns 31 shares of the company’s stock valued at $32,000 after purchasing an additional 24 shares in the last quarter. New England Capital Financial Advisors LLC grew its holdings in shares of Eli Lilly and Company by 142.9% during the 4th quarter. New England Capital Financial Advisors LLC now owns 34 shares of the company’s stock valued at $37,000 after purchasing an additional 20 shares during the last quarter. Finally, Maseco LLP lifted its stake in Eli Lilly and Company by 466.7% in the first quarter. Maseco LLP now owns 34 shares of the company’s stock worth $31,000 after purchasing an additional 28 shares during the last quarter. 82.53% of the stock is currently owned by hedge funds and other institutional investors.

Key Headlines Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Obesity-pill momentum: Lilly is reportedly narrowing Novo Nordisk’s early lead in the oral weight-loss market. Investor enthusiasm is being supported by expectations that Lilly’s obesity portfolio can extend its leadership beyond injectable GLP-1 treatments. Eli Lilly, Stock Of The Day, Is Erasing Novo’s Early Lead In Weight-Loss Pills
• Positive Sentiment: Retatrutide progress: Positive trial developments for retatrutide, Lilly’s next-generation obesity and metabolic-disease candidate, have prompted the company to lift related guidance. The drug could strengthen Lilly’s long-term growth outlook if late-stage results and regulatory progress remain favorable. Eli Lilly Lifts Guidance on Retatrutide Trial Wins
• Positive Sentiment: Pipeline expansion through licensing: Lilly entered a global collaboration with OmniAb for an ion-channel discovery program. The agreement, which includes potential milestone payments of up to $370 million, adds another avenue for future drug development and demonstrates continued investment in external innovation. OmniAb Enters Global Collaboration and License Agreement With Eli Lilly
• Positive Sentiment: CNS pipeline transaction: Lilly paid AlzeCure a $10 million upfront amount in an initial transaction involving small-molecule candidates for Alzheimer’s disease and pain, broadening Lilly’s pipeline beyond its core diabetes and obesity franchises. AlzeCure Receives a USD 10 Million Upfront Payment and Completes Initial Transaction With Lilly
• Neutral Sentiment: Lilly appointed Tayllit Aherdan to oversee operations in the United Arab Emirates, Qatar and Kuwait. The move supports regional execution but is unlikely to materially affect near-term earnings. Lilly Appoints Tayllit Aherdan
• Negative Sentiment: Analysts continue to flag Lilly’s elevated valuation, competition from Novo Nordisk and other obesity-drug developers, and potential pricing and patent pressures. With shares having already delivered substantial long-term gains, strong future growth may be required to justify additional upside. Can Eli Lilly Stay Undervalued If Growth Keeps Delivering?

Analyst Upgrades and Downgrades

LLY has been the topic of a number of recent analyst reports. Sanford C. Bernstein increased their price objective on Eli Lilly and Company from $1,300.00 to $1,385.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 14th. Morgan Stanley restated an “overweight” rating and set a $1,419.00 target price on shares of Eli Lilly and Company in a research report on Thursday, August 6th. Leerink Partners raised their price target on Eli Lilly and Company from $1,119.00 to $1,232.00 and gave the company an “outperform” rating in a report on Thursday, June 25th. JPMorgan Chase & Co. lifted their price target on Eli Lilly and Company from $1,300.00 to $1,400.00 and gave the company an “overweight” rating in a research report on Tuesday, July 7th. Finally, Truist Financial upped their price objective on shares of Eli Lilly and Company from $1,370.00 to $1,376.00 and gave the stock a “buy” rating in a research report on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, twenty-four have issued a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Eli Lilly and Company presently has a consensus rating of “Moderate Buy” and a consensus price target of $1,292.18.

About Eli Lilly and Company

Eli Lilly and Company (NYSE: LLY) is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.